Protagonist TherapeuticsPTGX 51 Altman Z-Score is 112.28 as of Jul. 01, 2026, which is 953% above its 10-year median of 10.66. GuruFocus rates PTGX with a GF Score™ of 51/100 and a GF Value™ of $58.69 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 929 Biotechnology companies, Protagonist Therapeutics ranks better than 99.03% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 112.28 is strong.
Protagonist Therapeutics has a Altman Z-Score of 112.28, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Protagonist Therapeutics's Altman Z-Score or its related term are showing as below:
PTGX'
s Altman Z-Score Range Over the Past 10 Years
Min: -5.49 Med: 10.66 Max: 112.28
Current: 112.28
During the past 12 years, Protagonist Therapeutics's highest Altman Z-Score was 112.28. The lowest was -5.49. And the median was 10.66.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTGX vs IMVT, SYRE, MIRM: Altman Z-Score Comparison
For the Biotechnology subindustry, Protagonist Therapeutics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagonist Therapeutics Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Protagonist Therapeutics (PTGX) has a Altman Z-Score of 112.28 as of Jul. 01, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Protagonist Therapeutics and its competitors. This is 953% above median its historical median of 10.66. According to the industry distribution chart, Protagonist Therapeutics ranks #9 out of 929 companies in the Biotechnology industry, placing it in the top 1%.
Is Protagonist Therapeutics' Altman Z-Score too high?
Protagonist Therapeutics' current Altman Z-Score of 112.28 is 953% above median its 10-year median of 10.66. The Biotechnology industry median Altman Z-Score is 2.60. Protagonist Therapeutics' value of 112.28 is 4218.5% above this industry median. Based on the distribution chart, Protagonist Therapeutics ranks #9 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protagonist Therapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Altman Z-Score compare to IMVT and SYRE?
According to the Biotechnology industry distribution chart, Protagonist Therapeutics ranks #9 out of 929 companies for Altman Z-Score. This places Protagonist Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.60. Protagonist Therapeutics' value of 112.28 is 4218.5% above this benchmark. While the company's 10-year median is 10.66 vs. the industry median of 2.60, Protagonist Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.60, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagonist Therapeutics's current Altman Z-Score of 112.28 is 4218.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Protagonist Therapeutics and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagonist Therapeutics's current Altman Z-Score is 112.28, which is 953% above median its own 10-year median of 10.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $58.69, compared to a current price of $122.58 — trading 108.9% above its estimated fair value. The current Altman Z-Score is 112.28, which is 953% above median its 10-year median of 10.66 and 4218.5% above the Biotechnology industry median of 2.60. Protagonist Therapeutics' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current Altman Z-Score is 112.28 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protagonist Therapeutics (PTGX) Overvalued in 2026?
Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued.
The current stock price of $122.58 is trading 108.9% above its estimated GF Value™ of $58.69.
GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.
Key valuation signals for PTGX:
Altman Z-Score: 112.28 (953% above median its 10-year median of 10.66)
GF Value™: $58.69 vs. price of $122.58 (108.9% above fair value)
Industry Position: 4218.5% above the Biotechnology median (#9 of 929)
No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
51GF Score
Get the complete analysis for PTGX
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTGX has been successfully added to your 
